JAZZ Jazz Pharmaceuticals plc
Price (delayed)
$110.8
Market cap
$6.73B
P/E Ratio
12.23
Dividend/share
N/A
EPS
$9.06
Enterprise value
$10.46B
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration
Highlights
Jazz Pharmaceuticals's quick ratio has soared by 135% YoY and by 10% from the previous quarter
The company's EPS rose by 38% YoY and by 22% QoQ
The company's debt rose by 7% YoY
Key stats
What are the main financial stats of JAZZ
Market
Valuations
Earnings
Shares outstanding
60.73M
Market cap
$6.73B
Enterprise value
$10.46B
Price to earnings (P/E)
12.23
Price to book (P/B)
1.64
Price to sales (P/S)
1.68
EV/EBIT
14.8
EV/EBITDA
7.66
EV/Sales
2.57
Revenue
$4.07B
Gross profit
$3.62B
Operating income
$716.63M
Net income
$560.12M
EBIT
$706.79M
EBITDA
$1.37B
Free cash flow
$1.36B
Per share
Balance sheet
Liquidity
EPS
$9.06
EPS diluted
$8.65
Free cash flow per share
$21.96
Book value per share
$67.72
Revenue per share
$65.8
TBVPS
$89.59
Total assets
$12.01B
Total liabilities
$7.92B
Debt
$6.15B
Equity
$4.09B
Working capital
$3.59B
Debt to equity
1.5
Current ratio
4.46
Quick ratio
3.57
Net debt/EBITDA
2.73
Margins
Efficiency
Dividend
EBITDA margin
33.6%
Gross margin
89%
Net margin
13.8%
Operating margin
17.6%
Return on assets
4.8%
Return on equity
14.2%
Return on invested capital
9.1%
Return on capital employed
6.4%
Return on sales
17.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAZZ stock price
How has the Jazz Pharmaceuticals stock price performed over time
Intraday
1.67%
1 week
7.8%
1 month
-18.08%
1 year
3.14%
YTD
-10.03%
QTD
-10.75%
Financial performance
How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$4.07B
Gross profit
$3.62B
Operating income
$716.63M
Net income
$560.12M
Gross margin
89%
Net margin
13.8%
Jazz Pharmaceuticals's net income has increased by 35% YoY and by 21% QoQ
The company's net margin rose by 28% YoY and by 19% QoQ
The operating income rose by 24% year-on-year and by 11% since the previous quarter
JAZZ's operating margin is up by 17% year-on-year and by 9% since the previous quarter
Growth
What is Jazz Pharmaceuticals's growth rate over time
Valuation
What is Jazz Pharmaceuticals stock price valuation
P/E
12.23
P/B
1.64
P/S
1.68
EV/EBIT
14.8
EV/EBITDA
7.66
EV/Sales
2.57
The company's EPS rose by 38% YoY and by 22% QoQ
The P/E is 28% lower than the last 4 quarters average of 17.1
The price to book (P/B) is 29% lower than the 5-year quarterly average of 2.3 and 9% lower than the last 4 quarters average of 1.8
Jazz Pharmaceuticals's equity has increased by 10% YoY
The price to sales (P/S) is 35% less than the 5-year quarterly average of 2.6 and 7% less than the last 4 quarters average of 1.8
The revenue has grown by 6% YoY
Efficiency
How efficient is Jazz Pharmaceuticals business performance
The company's return on assets rose by 30% YoY and by 20% QoQ
The return on equity has increased by 20% year-on-year and by 17% since the previous quarter
The company's return on sales rose by 14% YoY and by 6% QoQ
JAZZ's ROIC is up by 11% YoY and by 3.4% QoQ
Dividends
What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAZZ.
Financial health
How did Jazz Pharmaceuticals financials performed over time
The total assets is 52% greater than the total liabilities
Jazz Pharmaceuticals's quick ratio has soared by 135% YoY and by 10% from the previous quarter
The company's current ratio has surged by 99% YoY and by 4.7% QoQ
The company's debt is 50% higher than its equity
Jazz Pharmaceuticals's equity has increased by 10% YoY
The company's debt rose by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.